Adjuvant multimodality immunotherapy in resected high-risk pancreatic ductal adenocarcinoma

Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest solid malignancies, with an estimated 67,000 new diagnoses in the United States in 2024 and a 5-year overall survival (OS) rate that still hovers below 15% for patients across all stages despite three decades of incremental progress (1). Only 15–20% of patients present with resectable disease, the only population for whom a cure is possible, and even in this group, recurrence after surgery is nearly universal without effective adjuvant therapy. Five-year OS after resection remains in the 10–20% range (2,3). Modified FOLFIRINOX (mFFX) in the adjuvant setting, validated by the PRODIGE 24 trial, represented meaningful progress, but most resected patients still recur, with a median disease-free survival (DFS) of around 21 months (4). In this context, the phase 1 trial by Hill and colleagues tested a biologically rational approach to improving outcomes in high-risk resected PDAC (5).

The study enrolled 19 patients with high-risk features- lymph node positivity and/or positive margins- into three cohorts using a modified 3+3 design: stereotactic body radiation therapy (SBRT) with full-dose FOLFIRINOX (FFX) (Cohort 1), SBRT with mFFX (Cohort 2), and cyclophosphamide plus GM-CSF-secreting pancreatic tumor vaccine (Cy/GVAX) followed by SBRT and mFFX with maintenance Cy/GVAX boosts until progression (Cohort 3). At a median follow-up of 36.2 months, the combination was well tolerated, with limited toxicity, and survival outcomes in Cohort 3 were encouraging. This is the first prospective trial of the quadruplet combination of GVAX, cyclophosphamide, SBRT, and mFFX in the adjuvant setting.

Scientific rationale: why this combination makes sense

The biology here rests on three mechanisms. First, GVAX, an allogeneic, irradiated pancreatic tumor cell vaccine engineered to secrete granulocyte-macrophage colony-stimulating factor (GM-CSF), stimulates dendritic cell maturation and primes T-cell responses against shared pancreatic tumor-associated antigens (6). Earlier work from the Johns Hopkins group showed that GVAX induces intratumoral tertiary lymphoid structures and CD8⁺ T cell infiltration, effectively converting immunologically cold PDAC into a more reactive phenotype (7). Second, low-dose cyclophosphamide selectively depletes CD4⁺CD25⁺ regulatory T cells (Tregs), releasing the brake on effector T-cell activity (8). Third, and most innovative, is the sequencing: SBRT precedes consolidative chemotherapy. The reasoning is straightforward; high-dose chemotherapy causes profound lymphopenia, which could undermine vaccine-mediated immune priming. The Johns Hopkins group demonstrated that SBRT produces significantly less lymphopenia than conventional fractionated chemoradiation, preserving the immunogenic synergy between vaccine-induced T-cell priming and radiation-mediated immunogenic cell death (5,9).

The immunostimulatory properties of SBRT extend beyond local tumor control. At ablative doses, SBRT induces immunogenic cell death, promotes the release of danger signals, and may create an in situ vaccine effect through neoantigen exposure, mechanisms that, when combined with a cellular vaccine platform, offer biological synergy (10). This is particularly relevant in the adjuvant setting, where microscopic residual disease may respond to immune surveillance in ways that bulky locally advanced tumors cannot.

Context and prior evidence

The GVAX platform in PDAC has a long translational history. Phase 2 data from the Johns Hopkins group established that a GM-CSF-based vaccine combined with 5-fluorouracil-based chemoradiation in high-risk resected PDAC achieved a median OS of 25 months and a DFS of 17 months, favorable outcomes for a cohort defined by lymph node positivity and positive margins (11). The critical limitation was the immunosuppressive effect of conventional chemoradiation, which likely blunted vaccine efficacy. This observation directly motivated the switch to SBRT in the current trial. In subsequent work, combination strategies incorporating nivolumab alongside Cy/GVAX demonstrated that intratumoral CD137⁺ activated T cell density correlated with improved OS, and that adding a CD137 agonist to Cy/GVAX/nivolumab numerically improved both DFS and OS. However, sample sizes remained limited (12). These findings place Hill et al.’s current work within a coherent research trajectory.

Design strengths and limitations

Several design elements are worth noting. The cohort sequencing logic, which isolated the contribution of GVAX by comparing Cohort 3 to Cohorts 1 and 2, was well conceived, even if the small sample size limits formal inference. The 36.2-month median follow-up is meaningful for a disease where recurrence peaks in the first 2 years. The decision to anchor the SBRT dose to the tumor bed delineated by surgical clips, rather than broad-field irradiation, reflects mature clinical thinking about minimizing lymphopenia while maximizing locoregional dose delivery.

However, several limitations constrain interpretation. The 19-patient sample, appropriate for a phase 1 safety and feasibility objective, was underpowered to assess survival, as the authors acknowledge. The single-institution design at a high-volume center with specialized expertise in both GVAX administration and SBRT delivery may limit generalizability; these modalities require infrastructure and coordination absent at most community oncology programs. Critically, we do not yet have published immune-correlate data from Cohort 3 to confirm the anticipated T-cell activation mechanism in vivo; a gap that future studies must close. Additionally, while the cohort selection criteria of high-risk features (positive nodes, positive margins) appropriately target patients at greatest risk of recurrence, it also introduces prognostic heterogeneity, and the absence of genomic profiling data limits our ability to identify subgroups most likely to benefit from immunotherapy, an increasingly important consideration given the known prognostic significance of BRCA2, ATM, and CDKN2A germline variants in PDAC (13).

Implications for patient selection and future trial design

Early-onset PDAC, defined as diagnosis at 60 years or younger, carries a higher prevalence of germline susceptibility variants. Whether germline status modifies immunotherapy responsiveness is clinically pressing (14). This group has characterized the yield of germline testing in early-onset PDAC cohorts and noted that germline variant carriers may have distinct tumor immune microenvironments, a consideration that should be prospectively embedded into future immunotherapy trials in resected PDAC (14). Comprehensive germline evaluation should become standard within the eligibility and stratification framework of phase 2/3 adjuvant immunotherapy trials.

Furthermore, the metabolic co-morbidity burden carried by PDAC patients, including high rates of new-onset diabetes, metabolic syndrome, and cardiovascular risk, has emerged as a potential modulator of treatment tolerance and immune function. We and others have documented the cumulative impact of metabolic syndrome traits on oncologic outcomes in cancer populations, a finding that invites prospective incorporation of metabolic phenotyping into immunotherapy trial design (15). For a regimen of this complexity, combining vaccine, immunomodulatory chemotherapy, radiation, and consolidative chemotherapy, a patient’s baseline metabolic and immune reserve may substantially influence both tolerance and response.

Looking ahead, the logical next step is a randomized phase 2 trial comparing adjuvant Cy/GVAX/SBRT/mFFX with adjuvant mFFX alone, stratified by high-risk features, germline status, and metabolic phenotype, with pre-specified immune-correlate endpoints including intratumoral tertiary lymphoid structure density, CD8⁺ T cell infiltration, and circulating Treg depletion. Integration with checkpoint inhibitor backbones, particularly programmed death-1 (PD-1) or lymphocyte-activation gene 3 (LAG-3) inhibitors, should be incorporated into an arm design given the known upregulation of programmed death-ligand 1 (PD-L1) following GVAX administration (7). The emerging personalized vaccine space, including mRNA neoantigen vaccines such as cevumeran, may also offer a complementary platform to allogeneic whole-cell approaches in future adjuvant trial designs (16).

Conclusions

Hill and colleagues have generated hypothesis-generating data from a carefully reasoned, biologically grounded phase 1 trial (5). The tolerability signal is encouraging, and the survival outcomes in the Cy/GVAX-containing cohort are sufficiently promising to justify phase 2 investigation. The key open questions—whether the immunological mechanism operates as theorized in vivo, which genomic and metabolic subgroups benefit most, and whether the combination is deliverable at scale beyond specialized academic centers—must be addressed prospectively. This work represents a meaningful signal in a field where signals have been hard to come by.

Acknowledgments

None.

Footnote

Provenance and Peer Review: This article was commissioned by the editorial office, Translational Gastroenterology and Hepatology. The article has undergone external peer review.

Peer Review File: Available at https://tgh.amegroups.com/article/view/10.21037/tgh-2026-0046/prf

Funding: None.

Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at https://tgh.amegroups.com/article/view/10.21037/tgh-2026-0046/coif). The authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.

References

1. Mannucci A, Goel A. Advances in pancreatic cancer early diagnosis, prevention, and treatment: The past, the present, and the future. CA Cancer J Clin 2026;76:e70035. [Crossref] [PubMed]
2. Neoptolemos JP, Stocken DD, Bassi C, et al. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA 2010;304:1073-81. [Crossref] [PubMed]
3. Conroy T, Castan F, Lopez A, et al. Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer: A Randomized Clinical Trial. JAMA Oncol 2022;8:1571-8. [Crossref] [PubMed]
4. Conroy T, Hammel P, Hebbar M, et al. FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer. N Engl J Med 2018;379:2395-406. [Crossref] [PubMed]
5. Hill CS, Parkinson R, Jaffee EM, et al. Phase 1 Study of Adjuvant Allogeneic Granulocyte-Macrophage Colony-Stimulating Factor-Transduced Pancreatic Tumor Cell Vaccine, Low-Dose Cyclophosphamide, and Stereotactic Body Radiation Therapy Followed by FOLFIRINOX in High-Risk Resected Pancreatic Ductal Adenocarcinoma. Int J Radiat Oncol Biol Phys 2025;121:930-41. [Crossref] [PubMed]
6. Bloom M, Shaikh AR, Sun Z, et al. Cancer Vaccination and Immune-Based Approaches in Pancreatic Cancer. Cancers (Basel) 2025;17:2356. [Crossref] [PubMed]
7. Lutz ER, Wu AA, Bigelow E, et al. Immunotherapy converts nonimmunogenic pancreatic tumors into immunogenic foci of immune regulation. Cancer Immunol Res 2014;2:616-31. [Crossref] [PubMed]
8. Reiss KA. Evaluation of cyclophosphamide/GVAX pancreas followed by listeria-mesothelin with or without nivolumab in patients with pancreatic cancer. Clin Cancer Res 2020;26:3541-51.
9. Wild AT, Herman JM, Dholakia AS, et al. Lymphocyte-Sparing Effect of Stereotactic Body Radiation Therapy in Patients With Unresectable Pancreatic Cancer. Int J Radiat Oncol Biol Phys 2016;94:571-9. [Crossref] [PubMed]
10. Marciscano AE, Haimovitz-Friedman A, Lee P, et al. Immunomodulatory Effects of Stereotactic Body Radiation Therapy: Preclinical Insights and Clinical Opportunities. Int J Radiat Oncol Biol Phys 2021;110:35-52. [Crossref] [PubMed]
11. Lutz E, Yeo CJ, Lillemoe KD, et al. A lethally irradiated allogeneic granulocyte-macrophage colony stimulating factor-secreting tumor vaccine for pancreatic adenocarcinoma. A Phase II trial of safety, efficacy, and immune activation. Ann Surg. 2011;253:328-335.
12. Heumann T, Judkins C, Li K, et al. A platform trial of neoadjuvant and adjuvant antitumor vaccination alone or in combination with PD-1 antagonist and CD137 agonist antibodies in patients with resectable pancreatic adenocarcinoma. Nat Commun 2023;14:3650. [Crossref] [PubMed]
13. Dal Buono A, Poliani L, Greco L, et al. Prevalence of Germline Mutations in Cancer Predisposition Genes in Patients with Pancreatic Cancer or Suspected Related Hereditary Syndromes: Historical Prospective Analysis. Cancers (Basel) 2023;15:1852. [Crossref] [PubMed]
14. Ehsan H. Germline testing in patients with early-onset pancreatic cancer (EOPC). J Clin Oncol 2024;42:639.
15. Krishnan A. Differential and cumulative impact of metabolic syndrome traits on cardiovascular, renal, and mortality outcomes in cancer patients. J Clin Oncol 2025;43:11060.
16. Rojas LA, Sethna Z, Soares KC, et al. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Nature 2023;618:144-50. [Crossref] [PubMed]